Nervous System Neoplasms clinical trials
The registry lists 19 studies for Nervous System Neoplasms across 8 countries. 8 are recruiting or about to start. 4 of them are mainly about Nervous System Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its 29 narrower conditions too, such as Brain Neoplasms: 4,556 studies, 1,143 open.
Get an email when these change. Save the Nervous System Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
TVAX Biomedical (2) · BBB-Therapeutics B.V. (1) · Sidney Kimmel Cancer Center at Thomas Jefferson University (1) · Cerenome (1) · GlaxoSmithKline (1) · Columbia University (1) · Ludwig-Maximilians - University of Munich (1) · University of California, Irvine (1)
What is being tested here
Drugs under test in Nervous System Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026FUS Etoposide for DMG · Columbia University
- Feb 2027Second Window Indocyanine Green for All Nervous System Tumors · Abramson Cancer Center at Penn Medicine
- Jul 2027Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases · Cerenome
Who these studies take
Of the 6 Nervous System Neoplasms studies recruiting now, 4 (67%) set no upper age limit and 2 (33%) stop at 75 or younger. 3 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (50%) | 3 (50%) |
| 18 | 6 (100%) | 6 (100%) |
| 30 | 4 (67%) | 4 (67%) |
| 40 | 4 (67%) | 4 (67%) |
| 50 | 4 (67%) | 4 (67%) |
| 65 | 4 (67%) | 4 (67%) |
| 75 | 4 (67%) | 4 (67%) |
| 85 | 4 (67%) | 4 (67%) |
Across all 19 studies, recruiting or not: 26% stop at 75 or younger and 21% at 65; 37% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 19 of 19. search them.
- Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesRecruitingNCT07098806Phase 1/21 country
- PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicTheRecruitingNCT078270011 country
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingNCT03911388Phase 11 country
- Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNot yet recruitingNCT07773454Phase 1
- FUS Etoposide for DMGRecruitingNCT05762419Phase 11 country
- Second Window Indocyanine Green for All Nervous System TumorsEnrolling by invitationNCT05746104Phase 11 country
- Florida Center for Brain Tumor ResearchRecruitingNCT008111481 country
- Creation of a Clinical Database on Primary Nervous System TumorsRecruitingNCT045167201 country
- Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer PatientsCompletedNCT00437372Phase 11 country
- Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV GliomaCompletedNCT01290692Phase 21 country
- Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV GliomaCompletedNCT01081223Phase 1/21 country
- Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved LymphomaCompletedNCT00000689Phase 11 country
- Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain TumorsCompletedNCT01032200Phase 21 country
- A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain MetastasesCompletedNCT00649207Phase 13 countries
- Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053
- Protective Ventilation in Neurosurgery, a Pilot StudyCompletedNCT02450019Not applicable1 country
- Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System TumorsCompletedNCT01751308Phase 1/22 countries
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.CompletedNCT01386580Phase 1/24 countries
- Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma PatientsStatus unknownNCT015792531 country